Highly Expertise
At Syna we have extensive experience and know-how in all phases of biosimilar medicines, from development to manufacturing and commercialisation.


We work with the most advanced technology as well as a large-scale industrial plant specialised in injectable and lyophilised products

Impact on Healthcare

Biosimilars are used to treat serious and chronic illnesses

Their safety and efficacy is the same as the original drug

European Commission has drafted an informative flyer


Annual growth up to 2021

Biosimilar drugs are an attractive option to reduce costs of health systems


Approved in Europe

The biosimilar is one of the most important technological challenges of recent years.

Dr Andreu Soldevila
CEO of Syna